Use of LDH and autoimmune side effects to predict response to ipilimumab treatment

• Verfasst von: Dick, Julika [VerfasserIn]
• Verfasst von: Lang, Nina [VerfasserIn]
• Verfasst von: Schulz, Christof [VerfasserIn]
• Verfasst von: Enk, Alexander [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Titel: Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
• Verf.angabe: J Dick, N Lang, A Slynko, A Kopp-Schneider, C Schulz, A Dimitrakopoulou-Strauss, AH Enk, and JC Hassel
• Umfang: 12 S.
• Fussnoten: Gesehen am 28.02.2018
• Titel Quelle: Enthalten in: Immunotherapy
• Jahr Quelle: 2016
• Band/Heft Quelle: 8(2016), 9, S. 1033-1044
• ISSN Quelle: 1750-7448
• DOI: doi:10.2217/imt-2016-0083
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1570261768

Abstract

Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. Methods: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data. Results: A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit. Conclusion: Changes in LDH level and side effects correlate with response to therapy and survival.